-
Canan Schuman, PharmD/PhD
Posts
Regeneron’s Praluent sidekick nabs speedy FDA review, with February PDUFA date
Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of...
A look at Inovio’s Philly local coronavirus vaccine-in-progress
Operation Warp Speed, the federal government’s multi-agency push to develop a COVID-19 vaccine, is promising to provide 300 million doses by January 2021. That means...
Israeli scientist uses microbubbles to explode cancer cells
An international team of researchers led by an Israeli scientist has developed a noninvasive technology to kill breast cancer cells, an innovation that in the...
Bausch Health Announces Its Intention To Spin Off Its Eye Health Business Into An Independent Publicly Traded Company
LAVAL, QC, Aug. 6, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced that it intends to spin...
Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19
FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ — Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of...
Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst
On the heels of Pfizer’s $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in...
Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead
Headed up by Scott Clarke, an ex-Roche exec who served as its global head of oncology partnering for Asia and emerging markets, the cancer immunotherapy...
The CRA’s Guide to Monitoring Clinical Research
The guide that has trained thousands of CRAs is updated! The CRA’s Guide to Monitoring Clinical Research: A definitive resource for building mastery and complying...
Novartis promises zero profit for 15 symptomatic COVID-19 drugs in low-income countries
Novartis’ generic hydroxychloroquine may have little use in COVID-19, but the Swiss pharma still wants to contribute its low-cost drugs in some way in the...
Imvax Inc. Raises $112 Million in Series C Financing
Imvax Inc. Raises $112 Million in Series C Financing Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research...